Short Interest in Scienture Holdings, Inc. (NASDAQ:SCNX) Declines By 36.4%

Scienture Holdings, Inc. (NASDAQ:SCNX) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 1,022,272 shares, a decrease of 36.4% from the August 15th total of 1,607,698 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average trading volume of 400,597 shares, the short-interest ratio is presently 2.6 days.

Scienture Stock Performance

SCNX traded down $0.01 during trading on Thursday, reaching $0.32. 235,137 shares of the company were exchanged, compared to its average volume of 2,214,139. The stock has a market cap of $13.18 million, a P/E ratio of -0.15 and a beta of 3.25. The firm has a 50 day moving average of $0.39 and a 200 day moving average of $0.39. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15. Scienture has a 52 week low of $0.24 and a 52 week high of $2.60.

Scienture (NASDAQ:SCNX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million.

Institutional Investors Weigh In On Scienture

An institutional investor recently bought a new stake in Scienture stock. Susquehanna International Group LLP purchased a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned about 0.57% of Scienture as of its most recent SEC filing. Hedge funds and other institutional investors own 5.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $1.50.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.